Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Ibrutinib, a Bruton’s tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and routine health-care are commonly observed in oncology. Herein we report real-world results for 95 poor prognosis Swedi...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Haematologica
Main Authors: Winqvist, Maria, Asklid, Anna, Andersson, PO, Karlsson, Karin, Karlsson, Claes, Lauri, Birgitta, Lundin, Jeanette, Mattsson, Mattias, Norin, Stefan, Sandstedt, Anna, Hansson, Lotta, Österborg, Anders
Formáid: Artigo
Teanga:Inglês
Foilsithe: Ferrata Storti Foundation 2016
Ábhair:
Articles
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5479603/
https://ncbi.nlm.nih.gov/pubmed/27198718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.144576
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla